STEPHEN A SHERWIN
CIK 1079462 · Chairman and CEO · last filed 2026-06-11
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$8.76M
Companies
9
Total Filings
105
Lifetime Open-Market Net
-$28.66M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BIIB | Director | 15,193 | $209.23 | $3.18M | -$10.17M | 30 | 2026-06-11 |
| NBIX | Director | 30,860 | $180.79 | $5.58M | -$18.51M | 40 | 2026-06-09 |
| CHINOOK THERAPEUTICS, INC. (ADRO) Delisted | Director | — | — | — | $0 | 6 | 2020-05-28 |
| Neon Therapeutics, Inc. (NTGN) Delisted | Director | 0 | — | — | $0 | 2 | 2020-05-06 |
| RIGL | Director | — | $39.07 | — | $0 | 9 | 2016-05-12 |
| VSTM | Director | 208 | $6.01 | $1.3K | $21.4K | 4 | 2015-06-16 |
| Fresh Tracks Therapeutics, Inc. (VICL) Delisted | Director | 3,143 | — | — | $70 | 2 | 2015-05-26 |
| ANI PHARMACEUTICALS INC (BPAX) Delisted | Director | 15,374 | — | — | $0 | 4 | 2012-03-30 |
| CELL GENESYS INC (CEGE) Delisted | Chairman and CEO | 30,000 | — | — | $0 | 4 | 2009-10-15 |
Recent Filings · Page 8 of 11
105 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2013-05-28 | Fresh Tracks Therapeutics, Inc. (VICL) Delisted | Mixed | +7,003 | $70 | EDGAR |
| 2013-05-28 | RIGL | Grant (A) | — | $0 | EDGAR |
| 2013-05-23 | NBIX | Grant (A) | — | $0 | EDGAR |
| 2013-04-01 | NBIX | Mixed | +1,531 | $2 | EDGAR |
| 2013-03-25 | BIIB | Sell (S) | −1,500 | -$265.3K | EDGAR |
| 2013-03-06 | VSTM | Grant (A) | — | $0 | EDGAR |
| 2012-09-05 | BIIB | Sell (S) | −2,000 | -$291.8K | EDGAR |
| 2012-06-11 | BIIB | Grant (A) | +2,020 | $0 | EDGAR |
| 2012-06-05 | BIIB | Sell (S) | −2,500 | -$316.1K | EDGAR |
| 2012-05-24 | RIGL | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.